LGVN Longeveron

Longeveron to Participate in Upcoming 2022 Investor Conferences

Longeveron to Participate in Upcoming 2022 Investor Conferences

MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that Company leadership will participate in three upcoming investor conferences.

A.G.P.’s Virtual Biotech Conference

Format: One-on-one Meetings

Date: Wednesday, November 30, 2022

Location: Virtual

The Benchmark Company 11th Annual Discovery One-on-One Investor Conference

Format: One-on-one Meetings

Date: Thursday, December 1, 2022

Location: New York, NY

RHK 2022 Disruptive Growth Conference

Format: Company Presentation

Date: Tuesday, December 6, 2022

Location: New York, NY

Time: 10:40-11:00 a.m. ET

A live webcast of the presentation at the RHK 2022 Disruptive Growth Conference can be accessed by visiting “Events & Presentations” in the Investors section of Longeveron’s website at . A replay of the webcast will be available shortly following the conference.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has a multi-modal mechanism of action that is pro-vascular, pro-regenerative, and anti-inflammatory, promoting tissue repair and healing with broad potential applications across a spectrum of disease areas. Longeveron is advancing Lomecel-B™ through clinical trials in three indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s Disease, and Aging Frailty. Additional information about the Company is available at .

Investor Contact:

Elsie Yau

Stern IR, Inc.

212-698-8700

Source: Longeveron Inc



EN
29/11/2022

Underlying

LGVNLongeveron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Longeveron

 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Appoints Than Powell as Chief Business Officer

Longeveron® Appoints Than Powell as Chief Business Officer Mr. Powell to oversee Longeveron’s partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company’s overall business strategy, Alzheimer’s disease program partnering efforts, and international strategy fo...

13h / 54m 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Cli...

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS) Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II results are positiveU.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan drug designation, and Fast track designationLaromestrocel HLHS program addresses...

June 24, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Per...

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa’el Hashad, CEO, will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025. Details for the Company’s corporate presentation: Pre-recorded presentation available on-demand Monday, June 16, at 7:00 a.m. ETLon...

June 9, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® to Attend BIO International Convention 2025

Longeveron® to Attend BIO International Convention 2025 Focus on potential partnership and strategic opportunities for the Company’s stem cell therapy program for Alzheimer’s diseaseRecent Type B meeting with FDA provided alignment on a planned single, pivotal Phase 2/3 clinical trial, which if positive, would be acceptable for Biological License Application (BLA) submission for Alzheimer’s diseaseInitiation of planned single, pivotal Phase 2/3 clinical trial in mild Alzheimer’s disease anticipated in 2H 2026, contingent upon obtaining non-dilutive funding and/or partnering supportResults f...

May 20, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone ...

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapyStem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer’s disease and HLHS, a rare pediatric disease and orphan-designated indication MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selecte...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch